Safety of statin administration in patients with severe diseases associated with metabolic syndrome

A retrospective cohort study was carried out to elucidate the safety of statin administration in patients suffering from polymorbidity with high coronary risk and severe diseases associated with metabolic syndrome. The study included 89 patients aged 39-80 years who regularly took statins in individually selected doses for the period of 1-3 years and underwent routine laboratory monitoring of efficiency and safety of the therapy at the out-patient central regional hospital. A longterm statin therapy, even in small doses, contributed to statistically significant reduction in the total cholesterol level and was safe for polymorbid patients with high coronary risk. This was proven by the lack of significant increase in the number of biochemical indicators including level of transaminases, bilirubin, urea, uric acid, and creatinine during the treatment. Patients who regularly took atorvastatin achieved the target level of total cholesterol 1.5 times more often with shorter duration of treatment than those who took other statins.